Format

Send to

Choose Destination
See comment in PubMed Commons below
Antivir Chem Chemother. 2014 Jan 29;23(4):145-9. doi: 10.3851/IMP2551.

Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors.

Author information

  • 1Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.

Abstract

Persistence of HIV-1 in latently infected CD4(+) T-cells prevents eradication in HIV-infected treated patients. Latency is characterized by a reversible silencing of transcription of integrated HIV-1. Several molecular mechanisms have been described which contribute to latency, including the establishment and maintenance of repressive chromatin on the HIV-1 promoter. Histone deacetylation is a landmark modification associated with transcriptional repression of the HIV-1 promoter and inhibition of histone deacetylase enzymes (HDACs) reactivates latent HIV-1. Here, we review the different HDAC inhibitors that have been studied in HIV-1 latency and their therapeutic potential in reactivating latent HIV-1.

PMID:
24318952
PMCID:
PMC3947511
DOI:
10.3851/IMP2551
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Support Center